Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

A. A. Brandes, A. Tosoni, G. Cavallo, R. Bertorelle, V. Gioia, E. Franceschi, M. Biscuola, V. Blatt, L. Crinò, M. Ermani

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)'. Together they form a unique fingerprint.

Medicine & Life Sciences